ZIM Integrated Shipping (ZIM) to be acquired by Hapag-Lloyd for $35 per share in $4.2 bln cash deal

 

 

 

 

• Chart the day before, Fri 13 Feb 2026 

 

  

Hapag-Lloyd (OTC: HPGLY) is buying Israeli competitor Zim Integrated Shipping Services for $4.2 billion as the shipping firm looks to bolster its capacity.

Germany-based Hapag-Lloyd said Monday that it signed a deal to buy Zim for $35 a share in cash, a 58% premium to Zim’s closing price of $22.20 on Friday. The total deal price of around $4.2 billion will be funded from cash reserves and external financing of up to $2.5 billion.

The combined business will have a standing capacity of more than 3 million twenty-foot equivalent units, the standard form of measurement in container shipping, and more than 400 vessels. Hapag-Lloyd currently has vessel capacity of 2.5 million TEU and 305 vessels, according to the company’s website.

The deal is expected to be completed by the end of this year, Hapag-Lloyd said. Any deal will require the consent of the state of Israel, Zim shareholders and regulators.

Zim is considered a strategic asset for the Israeli state. As part of the deal, Israel’s special stake in Zim will be transferred to a carved-out container business, which will be owned by Israeli private-equity firm FIMI, Hapag-Lloyd said. The new container line will start with 16 vessels, according to Hapag-Lloyd.

The move comes after Zim appointed an independent board that has spent the last several months conducting a strategic review to assess a range of options, including a sale of the company, capital allocation options and other measures to maximize shareholder value.

Zim recently reported a sharp drop in third-quarter earnings as freight rates tumbled and container volumes slipped, with the company warning that fourth-quarter conditions had weakened.

IPOs this week : Feb 9 - 13, 26 (wk 7)

 IPOs expected to price

• AGI (AGBK), 

• Arko Petroleum (APC), and 

• Clear Street Group (CLRS) are expected to price their IPOs and begin to trade. 

IPO lockup expirations

The IPO lockup period expires for blocks of shares of 

• Bullish (BLSH), 

• Nasus Pharma (NSRX), and 

• Magnitude International (MAGH).

== SpyGlass Pharma (SGP) began trading on the Nasdaq on Fri 6 Feb 26

 

• SpyGlass Pharma (SGP) roared onto the public markets today, as its IPO of 9.375 mln shares priced at the $16 midpoint of its $15-$17 range, opened for trading at $24 (a 50% gain), and is currently trading near $29.
• The company's lead product candidate, the Bimatoprost Drug Pad-IOL System, targets the $13 bln glaucoma market by attaching drug-eluting pads to an intraocular lens implanted during routine cataract surgery, delivering three years of medication to solve the critical issue of patient non-adherence to daily drops.
• While SGP remains pre-revenue with a net loss of $27.3 mln for the first nine months of 2025, its growth strategy relies on leveraging a known drug (bimatoprost) and a standard surgical procedure to pursue a streamlined regulatory pathway.
• Beyond its lead asset, the company is advancing a "Drug Ring System" for standalone procedures, positioning its proprietary platform as a versatile, lifetime solution for chronic eye conditions.
• The enthusiastic investor reception reflects high confidence in a technology that integrates seamlessly into the existing cataract workflow without requiring surgeons to learn complex new techniques.
• Ultimately, the market is pricing in a "de-risked" commercialization path, supported by the company's plan to utilize existing CPT reimbursement codes to align provider economics with improved patient outcomes.
• SpyGlass, based in California, is making drug-device combinations for ocular conditions. One program is a lens implanted during cataract surgery. With the help of attached drug pads, it’s meant to treat glaucoma and ocular hypertension by slowly releasing a medication that lowers eye pressure. The therapy, codenamed BIM-IOL, is currently in two Phase 3 studies that started last month. SpyGlass expects to complete enrollment in 2027.

SpyGlass Pharma is a biopharmaceutical company focused on developing sustained drug delivery systems for chronic eye diseases, particularly glaucoma. Their approach uses a proprietary non-bioerodible platform to deliver medications long-term, often integrated with existing procedures like cataract surgery.Their main drug candidates, based on their pipeline and recent clinical advancements (as of early 2026), are:

• BIM-IOL System (Bimatoprost Drug Pad-Intraocular Lens System): This is their lead product candidate. It involves proprietary non-bioerodible drug pads attached to a monofocal intraocular lens (IOL), implanted during routine cataract surgery. It delivers bimatoprost (a prostaglandin analog) sustained over up to 3 years to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
  • It is in Phase III development, with two registrational trials (SGP-005 and SGP-006) having started randomization in January 2026.
  • Earlier trials (including 36-month first-in-human data) showed positive results, such as ~37% mean IOP reduction and safety comparable to standard cataract surgery.
• BIM-DRS (Bimatoprost Drug Ring System): This is their next-generation sustained-release implant. It is a removable and replaceable ring-shaped device for multi-year drug delivery (also bimatoprost). It targets a broader glaucoma population (including those not undergoing cataract surgery) and enables retreatment for patients previously treated with the BIM-IOL System. It has potential for lifelong disease management.
  • It is earlier in development, with first-in-human studies planned for 2026.

The company's platform is designed to be flexible for other approved medications and conditions (e.g., front/back of the eye diseases), with early/preclinical mentions of potential applications like postoperative steroids, NSAIDs, chronic uveitis, or age-related macular degeneration. However, the primary focus and most advanced candidates center on the bimatoprost-based systems for glaucoma.

OpenAI

OpenAI is not owned by a single entity, but rather operates under a complex hybrid structure. As of late 2025, it is controlled by the non-profit OpenAI Foundation (holding ~26-30%), while Microsoft holds a major stake (approx. 27-49%). Employees and other investors like Thrive Capital and Khosla Ventures hold the remaining equity. 

Key Details on Ownership & Structure:

• Non-Profit Control: The OpenAI Foundation (parent company) governs the for-profit, capped-profit subsidiary (OpenAI LP) to ensure the mission of safe AI development is prioritized over pure profit.

• Microsoft's Role: Microsoft has invested over $13 billion in total. While some reports indicate they hold 49% of the profit-sharing, other 2025 reports indicate a ~27-30% direct equity stake following company restructuring.

• Structure: OpenAI restructured into a for-profit "Group PBC" (Public Benefit Corporation) to allow for greater investment while keeping the non-profit as a majority stakeholder of the company's direction.

• Employee & Investor Ownership: A large portion of the company (roughly 30–47% depending on the report) is held by employees and various venture capital firms. 

Galaxy Digital (GLXY) reported earnings on Tue 3 Feb 26 (b/o)

• Galaxy Digital reports fiscal Q4 2025 results with non-GAAP EPS of -$1.08 and revenue of $10.2B, missing estimates; an SEC filing also shows a Q4 net loss of $482M, a full-year 2025 net loss of $241M, and equity capital up 38% to $3.0B as of year-end 2025.

  

Fat Brands (FAT) : suspension of Nasdaq trading

•  FAT Brands' stock  approaches the February 4 suspension of Nasdaq trading, directly resulting from the company's voluntary Chapter 11 bankruptcy filing on January 26, 2026. The delisting notice, issued by Nasdaq on January 28, cites non-compliance due to the bankruptcy and prior failure to maintain a $1 share price for 30 consecutive days. This has heightened investor concerns over liquidity and shareholder value in the restructuring process, which aims to address over $1.3 billion in debt through asset sales and negotiations. Recent volatility, including a prior surge on speculative trading, reversed as the delisting date nears, with no new positive developments reported to counter the negative implications.

TrueCar (NASDAQ: TRUE) has been acquired by Fair Holdings for approx. $227 million

TrueCar (NASDAQ: TRUE) acquired by founder-led strategic and financial investor group in all-cash go-private transaction in an all-cash deal valued at approximately $227 million, which closed in Jan 2026. Shareholders received $2.55 per share, a move led by founder Scott Painter, following a period of declining performance and a 60% drop in stock value prior to the announcement. 

ticker:  TRUE

Key details regarding TrueCar's shift:

• Going Private: The deal, announced in October 2025 and finalized in January 2026, marks the end of TrueCar's time as a publicly traded company.

• Founder Return: Scott Painter, founder of TrueCar, returned as CEO to lead the company.

• Performance Challenges: Before the acquisition, TrueCar faced significant pressure, with shares tumbling following quarterly losses, such as a 14% drop in August 2024 after a reported $13.5 million net loss.

• Restructuring: To combat poor performance, the company had implemented restructuring plans, including reducing staff and changing leadership, prior to the buyout.

• Shareholder Support: Major investors like AutoNation supported the takeover. 

The stock had previously seen volatility, including a 59% surge on the news of the buyout announcement in October 2025. 

Largest private companies in the U.S.

• Anthropic is backed ‌by Alphabet's Google and Amazon.com. 
• Founded in 2021 by former OpenAI staff, Anthropic's Claude models have built a ‍reputation among developers, ⁠particularly for coding tasks.

 

===OneStream (OS) to be acquired by Hg Capital ?

 

Bloomberg News reported, citing sources familiar with the matter, that buyout firm Hg Capital is nearing a deal to take the company private in a transaction valued around $4.3 billion, or about 6x projected 2026 revenue. This news emerged early Tuesday, sparking immediate buying interest as investors anticipated a premium offer for the financial software provider, which had been trading below its July IPO price. The development highlights renewed private equity interest in SaaS firms with stable cash flows, amplifying the premarket move amid light overall market volume.